Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

But A Comeback Remains Possible

Blenrep’s withdrawal will add to GSK’s blockbuster drought, and hopes of separate trial success for the BCMA-targeting drug in earlier stage myeloma may now be harder to achieve.

US FDA entrance sign — The FDA is now enforcing the accelerated approval commitments more strictly, including requests for withdrawals. • Source: Shutterstock, JHVEPhoto

GSK is to withdraw its multiple myeloma therapy Blenrep (belantamab mafodotin) from the US market following a US Food and Drug Administration request, as the drug has failed to show significant benefits for patients in a confirmatory study.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Blenrep US Withdrawal Is A Big Blow To GSK’s Blockbuster Hopes

But A Comeback Remains Possible

Read the full article – start your free trial today!

More from New Products

More from Scrip